CM
AQST icon

Crestline Management’s Aquestive Therapeutics AQST Stock Holding History

Crestline Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,503,294
Closed -$201M – 93
2018
Q3 		$201M Buy
+11,503,294
New +$190M 18.65% 2

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crestline Management's AQST Position: Q4 2018 in Review

Crestline Management sold out of Aquestive Therapeutics (AQST) in Q4 2018, closing a stake of 11,503,294 shares — an estimated $201M sold.

Crestline Management first reported a position in AQST in Q3 2018 and held it in 1 quarter. The position peaked at $201M in Q3 2018. 36 funds tracked by Wall St. Rank hold AQST as of Q4 2018.

  • Crestline Management reported no remaining Aquestive Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Crestline Management sold 11,503,294 Aquestive Therapeutics shares in Q4 2018, an estimated $201M.
  • Crestline Management first reported a position in Aquestive Therapeutics in Q3 2018 and held it in 1 quarter.
  • Crestline Management's Aquestive Therapeutics position peaked at $201M in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2018.

Based on Crestline Management's 13F filing for Q4 2018, filed 14 Feb 2019.